Compass Therapeutics

CMPXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$387.189 M

$2.15 +8.04%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$66.5M

Loss-making

Shares outstanding

180,087,915

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#78C4 TherapeuticsCCCC$412.4M
#79Fennec PharmaceuticalsFENC$403.8M
#80Compass TherapeuticsCMPX$387.2M
#81Lexeo TherapeuticsLXEO$377.7M
#82Palisade BioPALI$366.3M

Where these numbers come from

Share counts and financials for Compass Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.